Skip to main navigation

Investors
News Releases
Events & Presentations
Stock Information
Corporate Governance
SEC Filings
IR Resources

News Releases

News Releases

Year

February 7, 2019

Harpoon Therapeutics Announces Pricing of Initial Public Offering

January 2, 2019

Harpoon Therapeutics Announces Preliminary Safety and Pharmacology Data from its HPN424 Phase 1 Trial in Prostate Cancer

December 27, 2018

Harpoon Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering

December 2, 2018

Harpoon Therapeutics Presents Preclinical Data Supporting Development of HPN217, a New BCMA-Targeting TriTAC, at the 2018 American Society of Hematology (ASH) Annual Meeting

November 11, 2018

Harpoon Therapeutics Announces Closing of $70M Series C Financing

November 9, 2018

Harpoon Therapeutics Unveils ProTriTAC Platform: A Novel, Protease-Activated T Cell Engager Platform Designed to Access a Broad Landscape of Solid Tumor Targets

October 30, 2018

Harpoon Therapeutics Announces Appointment of Ms. Georgia L. Erbez to Chief Financial Officer and Promotion of Holger Wesche, Ph.D., to Chief Scientific Officer

October 11, 2018

Harpoon Therapeutics Appoints Ms. Julie Eastland, Biotech Industry Veteran, to Board of Directors

October 3, 2018

Harpoon Therapeutics Announces Appointment of Natalie R. Sacks, M.D., as Chief Medical Officer

September 18, 2018

Harpoon Therapeutics Announces Appointments to Board of Directors and Management Team

Pagination

Current page 1
Page 2
Next page
Last page

Email Alerts

RSS Feeds

Contact IR

Search

© 2019. Harpoon Therapeutics, Inc. All rights reserved.

Search Investor Relations